Evidence map›Paper›PMID 32191543›Full record

ArticleJCO clinical cancer informatics2020

CIViCpy: A Python Software Development and Analysis Toolkit for the CIViC Knowledgebase.

Alex H Wagner, Susanna Kiwala, Adam C Coffman, Joshua F McMichael, Kelsy C Cotto, Thomas B Mooney, Erica K Barnell, Kilannin Krysiak, Arpad M Danos, Jason Walker and 2 more

Open access · hybridAbstract read
In one paragraph

Article in JCO clinical cancer informatics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Accessing clinical-grade genomic classification data through the ClinGen Data Platform.Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing · 2023
    Article
  4. Age, Multiple Chronic Conditions, and COVID-19: A Literature Review.The journals of gerontology. Series A, Biological sciences and medical sciences · 2022
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Alex H WagnerMcDonnell Genome Institute, Washington University School of Medicine, St Louis, MO.
Susanna KiwalaMcDonnell Genome Institute, Washington University School of Medicine, St Louis, MO.
Adam C CoffmanMcDonnell Genome Institute, Washington University School of Medicine, St Louis, MO.
Joshua F McMichaelMcDonnell Genome Institute, Washington University School of Medicine, St Louis, MO.
Kelsy C CottoMcDonnell Genome Institute, Washington University School of Medicine, St Louis, MO.
Thomas B MooneyMcDonnell Genome Institute, Washington University School of Medicine, St Louis, MO.
Erica K BarnellMcDonnell Genome Institute, Washington University School of Medicine, St Louis, MO.
Kilannin KrysiakDepartment of Pathology and Immunology, Washington University School of Medicine, St Louis, MO.
Arpad M DanosMcDonnell Genome Institute, Washington University School of Medicine, St Louis, MO.
Jason WalkerMcDonnell Genome Institute, Washington University School of Medicine, St Louis, MO.
Obi L GriffithMcDonnell Genome Institute, Washington University School of Medicine, St Louis, MO.
Malachi GriffithMcDonnell Genome Institute, Washington University School of Medicine, St Louis, MO.
James S. McDonnell Foundation · USWashington University in St. Louis · US

Funding

Standardized and Genome-Wide Clinical Interpretation of Complex Genotypes for Cancer Precision MedicineU24CA237719 · NCI · WASHINGTON UNIVERSITY · PI GRIFFITH, OBI L. · 2019 to 2023
$3.8M
Genomic and Functional Identification of Chemotherapy Resistance Mechanisms in Small Cell Lung CancerU01CA231844 · NCI · WASHINGTON UNIVERSITY · PI GOVINDAN, RAMASWAMY, GRIFFITH, OBI L. · 2018 to 2022
$3.1M
DEVELOPMENT OF INFORMATICS RESOURCES FOR INTERPRETATION OF CLINICALLY ACTIONABLE VARIANTS IN CANCERU01CA209936 · NCI · WASHINGTON UNIVERSITY · PI GRIFFITH, OBI L. · 2016 to 2018
$1.0M
Integrated Analysis & Interpretation of Whole Genome Exome & Transcriptome SequenR00HG007940 · NHGRI · WASHINGTON UNIVERSITY · PI GRIFFITH, MALACHI · 2017 to 2019
$724k
TOOLS FOR NORMALIZING AND INTERPRETING THE CLINICAL ACTIONABILITY OF GENOMIC VARIANTSK99HG010157 · NHGRI · WASHINGTON UNIVERSITY · PI WAGNER, ALEX HANDLER · 2019 to 2020
$226k
A Collaborative Reporting Tool For Interpreting Genomic Events In Lung CancersF32CA206247 · NCI · WASHINGTON UNIVERSITY · PI WAGNER, ALEX HANDLER · 2017 to 2018
$122k
NCI NIH HHS F32 CA206247NCI NIH HHS U01 CA209936NCI NIH HHS U01 CA231844NCI NIH HHS U24 CA237719NHGRI NIH HHS K99 HG010157NHGRI NIH HHS R00 HG007940
6 · The paper itself

Abstract

purposePrecision oncology depends on the matching of tumor variants to relevant knowledge describing the clinical significance of those variants. We recently developed the Clinical Interpretations for Variants in Cancer (CIViC; civicdb.org) crowd-sourced, expert-moderated, and open-access knowledgebase. CIViC provides a structured framework for evaluating genomic variants of various types (eg, fusions, single-nucleotide variants) for their therapeutic, prognostic, predisposing, diagnostic, or functional utility. CIViC has a documented application programming interface for accessing CIViC records: assertions, evidence, variants, and genes. Third-party tools that analyze or access the contents of this knowledgebase programmatically must leverage this application programming interface, often reimplementing redundant functionality in the pursuit of common analysis tasks that are beyond the scope of the CIViC Web application.

methodsTo address this limitation, we developed CIViCpy (civicpy.org), a software development kit for extracting and analyzing the contents of the CIViC knowledgebase. CIViCpy enables users to query CIViC content as dynamic objects in Python. We assess the viability of CIViCpy as a tool for advancing individualized patient care by using it to systematically match CIViC evidence to observed variants in patient cancer samples.

resultsWe used CIViCpy to evaluate variants from 59,437 sequenced tumors of the American Association for Cancer Research Project GENIE data set. We demonstrate that CIViCpy enables annotation of > 1,200 variants per second, resulting in precise variant matches to CIViC level A (professional guideline) or B (clinical trial) evidence for 38.6% of tumors.

conclusionThe clinical interpretation of genomic variants in cancers requires high-throughput tools for interoperability and analysis of variant interpretation knowledge. These needs are met by CIViCpy, a software development kit for downstream applications and rapid analysis. CIViCpy is fully documented, open-source, and available free online.

Indexed as

MutationSoftwareDatabases, GeneticData MiningHigh-Throughput Nucleotide SequencingHumansKnowledge BasesNeoplasm ProteinsNeoplasmsPrecision MedicineUser-Computer InterfaceNeoplasm Proteins

Identifiers

PMID32191543
PMCPMC7113080
OpenAlexW3011643984

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.